Download PDF
Am J Perinatol 1992; 9(4): 247-249
DOI: 10.1055/s-2007-994781
ORIGINAL ARTICLE

© 1992 by Thieme Medical Publishers, Inc.

Zidovudine Pharmacokinetics During Pregnancy

Rhoda S. Sperling, John Roboz, Renata Dische, Demetra Silides, Ian Holzman, Edward Jew
  • Departments of Obstetrics, Gynecology and Reproductive Science, Neoplastic Diseases, Pathology, and Pediatrics, The Mount Sinai School of Medicine, New York, New York
Further Information

Publication History

Publication Date:
04 March 2008 (online)

Also available at
    Permissions and Reprints

ABSTRACT

As the indications for zidovudine (ZDV) treatment in human immunodeficiency virus-infected individuals expand, we anticipate an increased use of this drug during pregnancy. We report pharmacokinetics data from a patient studied both in the third trimester and intrapartum. ZDV peak-plasma levels and serum half-lives were comparable to nonpregnant adults. High concentrations of ZDV and its glucuronide metabolite were found in umbilical cord blood and in amniotic fluid.